Patient Education
Share your love
Loading Dose Adjustments and Treatment Switching Strategies in Retinal Vascular Diseases | Ophthalmology Times
This segment explores real-world approaches to loading dose protocols and dosing interval management when initiating or switching anti-VEGF therapies. The panel discusses how closely clinicians adhere to recommended loading regimens and the practical barriers to doing so, such as payer…
Advanced IOL Selection in a Low Night-Driving Patient With Bilateral Cataracts | Ophthalmology Times
This segment reviews a case-based roundtable discussion focused on advanced intraocular lens (IOL) selection in cataract surgery, highlighting the importance of patient-centered decision-making. The case involved a 69-year-old retired pastor engaged in foreign mission work who presented with bilateral cataracts,…
Reimagining dry eye care: Focus on sustained tear production | Ophthalmology Times
(Image Credit: AdobeStock/Chris Tefme) With dry eye disease (DED) presenting ongoing challenges for clinicians and patients, a recent Ophthalmology Times Viewpoints panel aimed to explore practical strategies for improving management and long-term outcomes. Kendall Donaldson, MD, MS, from Bascom Palmer…
How AI is reshaping ophthalmology in 2025 and beyond | Ophthalmology Times
(Image Credit: AdobeStock/ImageFlow) Artificial intelligence (AI) continues to evolve with improved diagnostic abilities, individualized patient treatments, and enhanced surgical accuracy. Some key developments include the analysis of retinal scans that provide earlier disease detection and the ability to spot tumors…
8 things to know about aflibercept 8 mg for retinal vascular disease | Ophthalmology Times
The US Food and Drug Administration (FDA) approved aflibercept 8 mg (EYLEA HD) for the treatment of patients with macular edema following retinal vein occlusion (RVO) with up to 8-week dosing after an initial dosing period last month. The latest…
From bench to bedside: Evolving realities of gene therapy for inherited retinal diseases | Ophthalmology Times
(Image Credit: AdobeStock/artacet) In recent years, gene therapy has emerged from the shadows of theoretical potential into the spotlight of clinical reality. The approval of voretigene neparvovec-rzyl (Luxturna; Spark Therapeutics) marked a historic moment as the first gene therapy for…
The Atrophy Advisor: An online tool to inform GA treatment decisions | Ophthalmology Times
(Image Credit: AdobeStock/NINENII) An online tool, Atrophy Advisor, was developed to guide physicians regarding treatments for patients with geographic atrophy (GA) associated with age-related macular degeneration (AMD). The tool, available at atrophyadvisor.com, integrates GA progression and personalized lifespan estimates to…
Screening for Demodex blepharitis: Integrating best practices into routine eye care | Ophthalmology Times
(Image Credit: AdobeStock) Demodex blepharitis is more common than previously thought, and proper diagnosis and management are important for effective patient care. Anne M. Zaki, MD, a cornea specialist in private practice at Desert Eye Specialists in Peoria, Arizona, moderated…
Dompé enrolls first patients in phase 3 study of isocyclosporin for treatment of atopic keratoconjunctivitis | Ophthalmology Times
(Image Credit: AdobeStock/kerkezz) Biopharmaceutical company Dompé has enrolled the first patients in its phase 3 study of isocyclosporin for the treatment of atopic keratoconjunctivitis (AKC). The multicenter, randomized, double-masked study will compare isocyclosporin against a vehicle control in the improvement…
Seeing the difference: Multimodal imaging for AMD and GA | Ophthalmology Times
(Image Credit: AdobeStock/jtamm) A timely and accurate diagnosis of retinal disease gives patients the best chance of achieving an optimal visual outcome. This is particularly true now, with the availability of drug treatments for geographic atrophy (GA) and inherited retinal…